相关实验视频

Updated: May 23, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

在心房的抗血栓治疗:抗凝固或不,这是一个问题

Fabian Wesołek¹, Przemysław Szyszka¹, Małgorzata Cichoń^1,2

¹First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.

Heart rhythm O2

|March 10, 2025

概括

心房动 (AFL) 似乎比心房动 (AF) 带来更低的中风风险. 需要进一步的研究来证实这些发现,并指导AFL患者的抗凝药治疗决策.

科学领域:

心脏病学心脏病学
电子生理学电子生理学
血栓形成研究研究

背景情况:

心房动 (AF) 是一种常见的心律失常,对健康和经济产生重大影响.
耳前 (AFL) 经常被忽视,但可以与AF并存或先于其发展.
目前的指导方针为AF和AFL提供了类似的抗凝药建议,因为AFL特定数据有限.

研究的目的:

审查和比较心房动 (AFL) 与心房动 (AF) 的血栓栓塞风险概况.
要突出AFL和AF之间关于中风风险的病理生理学和临床表现的差异.
为可能对AFL的抗凝策略进行重新评估提供信息.

主要方法:

对比AFL和AF患者的血栓栓塞瘤风险标志物和结果的研究文献综述.
对心声回声学发现的分析,包括自发心声回声学对比度 (SEC) 和左心房附属体 (LAA) 功能.
检查关于中风发病率和凝血标志物的观察数据.

主要成果:

与AF患者相比,AFL患者的SEC和血栓的患病率明显较低.
在AFL中观察到更好的左心房附属体 (LAA) 功能和较低的凝血标志物.
观察性研究表明,与AF相比,AFL的中风风险较低,特别是在较高的CHA2DS2-VASc得分时.

结论:

与AFL相关的血栓塞栓风险似乎低于AF的风险.
成功地切除洞腔柱性静脉,可以导致永久的AFL终止,与AF的慢性不同.
前性研究对于准确定义AFL的前血栓潜力和完善抗凝血指南至关重要.

关键词:

这是一种抗凝血药物.心房动是一种心房动.在心房动.一次性中风,中风.血栓塞栓症血栓塞栓症血栓塞栓症

更多相关视频

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...

Disturbances in Heart Rhythm

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...